| Literature DB >> 27368091 |
Abstract
Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.Mesh:
Substances:
Year: 2016 PMID: 27368091 DOI: 10.1016/j.cell.2016.06.036
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582